MLYS241220P12500
- 0.40
- 0.000.00%
Mineralys Therapeutics Newsroom
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics | 10-Q: Q3 2024 Earnings Report
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $26
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat's Potential in Hypertension Treatment
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript Summary
Mineralys Therapeutics Reports Q3 EPS ($1.13), Consensus (83c)
Mineralys Therapeutics 3Q Loss/Shr $1.13 >MLYS
Express News | Mineralys Therapeutics Q3 2024 GAAP EPS $(1.13) Misses $(0.83) Estimate
Express News | Mineralys Therapeutics Q3 Operating Income USD -60.106 Million
Earnings Scheduled For November 11, 2024
Insights Into Mineralys Therapeutics's Upcoming Earnings
Earnings Preview: MLYS to Report Financial Results Post-market on November 11
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $30
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $33
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Companies Like Mineralys Therapeutics (NASDAQ:MLYS) Are In A Position To Invest In Growth